Glaukos Corp (0001192448) Files Form 4 with SEC
Glaukos Corporation, a medical technology company focused on the development and commercialization of products designed to treat glaucoma, recently filed a Form 4 with the Securities and Exchange Commission. The significance of this filing lies in the fact that Form 4 is required to be filed with the SEC whenever there are changes in the holdings of company insiders, such as directors and officers, or any person holding more than 10% of the company’s stock.
Glaukos Corporation, with the ticker symbol GLAUKOS, is a leader in the treatment of glaucoma, a leading cause of blindness worldwide. The company’s innovative products aim to revolutionize the way glaucoma is treated, providing minimally invasive solutions for patients. For more information about Glaukos Corporation and its groundbreaking work in the field of ophthalmology, please visit their website at https://www.glaukos.com/.
Form 4 is a document filed with the SEC to disclose any changes in the ownership of company securities by insiders. This includes purchases, sales, and exercises of stock options. By requiring insiders to report their transactions, Form 4 helps promote transparency and accountability in the financial markets, allowing investors to make more informed decisions based on the actions of company insiders.
Read More:
Glaukos Corp (0001192448) Files SEC Form 4 – Issuer Update
